Related Experiment Video
Updated: Sep 29, 2025

Quantifying the Modulation of Elastase Enzyme Activity Through Colorimetric Analysis
Published on: January 17, 2025
Algae as a source of peptides inhibitors of the angiotensin-converting enzyme: a systematic review
Andreza P DE Amorim1, Gabrielly H DA Silva1, Romero M P Brandão2
1Universidade Federal Rural de Pernambuco/UFRPE, Laboratório de Tecnologia de Bioativos (LABTECBIO), Departamento de Morfologia e Fisiologia Animal, Av. Dom Manoel de Medeiros, s/n, 52171-900 Recife, PE, Brazil.
Abstract:
Hypertension is a factor that contributes to the risk of chronic diseases. The inhibition of angiotensin-I converting enzyme (ACE) is a useful therapeutic approach to the hypertension treatment. The algae have been an alternative for the production of ACE inhibitory (ACEi) peptides from enzymatic hydrolysis due to their protein-rich biomass. The aim of this study was to systematically review the literature regarding the production, composition and activity of ACEi peptides derived from algae proteins. Systematic database searches identified 648 related articles. Among these, only 14 were selected according to the eligibility criteria to this review. Macroalgae are more studied than microalgae as sources of ACEi peptides. Furthermore, hydrolysates by thermolysin or bromelain exhibited the highest ACEi activity compared to other enzymes. The main features of the peptides with high ACE inhibition are low molecular weight, short amino acids sequence and non-competitive inhibition pattern. In vivo studies using hydrolysates and peptides derived from algae proteins showed antihypertensive activity in spontaneously hypertensive rats (SHR). Thus, it is suggested that ACEi peptides derived from algae can be considered as potential antihypertensive.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Enzyme Inhibition
Antihypertensive Drugs: Angiotensin II Receptor Blockers

